{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-077876","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.921467+00:00","generated_at":"2026-06-17T19:13:57.018586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Invivyd FY2022 net loss $241.3M; advancing VYD222 mAb into clinic","bullets":["Cash, cash equivalents and marketable securities $372M as of Dec 31, 2022, expected to fund operations into H2 2024.","Net loss $241.3M ($2.23 per share) for FY2022 vs $226.8M ($5.32 per share) in FY2021.","R&D expenses $183.6M, down slightly from $190.4M in FY2021.","Advancing VYD222 into Phase 1 clinical trial in Q1 2023; in vitro data shows neutralizing activity against XBB.1.5.","Appointed Jeremy Gowler as COO and promoted Pete Schmidt to CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-077876","json":"https://secwatch.observer/filing/0001193125-23-077876.json","markdown":"https://secwatch.observer/filing/0001193125-23-077876.md","text":"https://secwatch.observer/filing/0001193125-23-077876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312523077876/0001193125-23-077876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312523077876/d450944d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T19:13:57.018586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c66263c40dbe9909abe314ee9e3fc279e8ac0b37","claim":"Invivyd, Inc. reported the year ended December 31, 2022 results: net income $241.3 million.","evidence_excerpt":"Net loss was $241.3 million for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312523077876/0001193125-23-077876-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$241.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}